Evaluation of recombinant human prourokinase in the treatment of acute pulmonary embolism (ERUPTE): a randomized single-blinded multicenter phase 2 trial

Zhi-Cheng Jing, M.D.
Guangdong Provincial People's Hospital
Guangzhou, China

Chun-Yan Cheng, M.D., Ph.D.
Guangdong Provincial People's Hospital
Guangzhou, China

Engineered hamster ovary cells expressing human cDNA produces recombinant human prourokinase (rhPro-UK) which showed superior thrombolytic effect than alteplase. In this presentation Dr. Jing discusses the teams aim of evaluationg the efficacy and safety of different intravenous doses is of rhPro-UK in the treatment of pulmonary embolism. Results from the multicenter trial used to assess the aim will be presented discussing details of mean systolic pulmonary arterial pressure comparing rhPro-UK 40 mg and 50mg with alteplase groups.